New cannabinoid-gabapentinoid conjugates and uses thereof
AssigneeLondon Pharmaceuticals and Research Corporation
InventorMahmoud Mohamed Abdrabo Moustafa
Life of this patent
Estimating the term…
Abstract
Cannabinoid-gabapentinoid conjugates and their formulations possessing dual synergistic pharmacological effects to control neuropathic pain, multiple sclerosis, seizures and postherpetic neuralgia, restless leg syndrome, trigeminal neuralgia, fibromyalgia, diabetic neuropathy, anxiety and bipolar disorders, schizophrenia, sleep disorders, and other related pathological conditions. The conjugates improve the therapeutic potential for both component compounds, while reducing the addiction and substance abuse problems commonly observed with each component, when prescribed independently, thereby providing a solution for cannabinoid and gabapentinoid substance abuse disorders.
Claims65
A compound of formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
- wherein:
- Canna is a cannabinoid that modulates one or more cannabinoid receptors, either as an agonist, biased agonist, antagonist, or with mixed actions,
- Gabapent is a gabapentinoid with a carboxylic acid functionality or its isostere or analogues connected through a three-carbon chain to an amino group or its isostere or analogues,
- linker is selected from the group consisting of:
- a hydrolysable covalent or ionic bond, or a linear, cyclic, or branched alkyl carbon chain, which is optionally functionalized or substituted or both, and is attached independently to the cannabinoid and gabapentinoid by a hydrolysable covalent or ionic bond;
- and
- wherein the cannabinoid may have one or more gabapentinoids each attached by a linker.
Dependencies are inferred from the claim text.